Momenta Pharma (MNTA) 12.02 $MNTA Momenta

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Momenta Pharma (MNTA) 12.02 $MNTA

Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 3:45PM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the Company's necuparanib program, at the 2016 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled to begin on Wednesday, September 7 at 1:45 p.m. ET.
WFC: 50.80 (+0.18), MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 11.3%
Tuhin Roy - Zacks Investment Research - Thu Aug 25, 7:25AM CDT
Momenta Pharmaceuticals Inc. (MNTA) moved big last session, as its shares jumped a little over 11% on the day.
GERN: 2.69 (unch), MNTA: 12.02 (+0.02)

Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.56 (+0.20), BIIB: 305.63 (-2.23), BMRN: 93.89 (-1.06), AMGN: 170.06 (-0.70), ABBV: 64.10 (-0.06), MNTA: 12.02 (+0.02), REGN: 392.55 (-2.67)

Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 7:02AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2016.
MNTA: 12.02 (+0.02)

Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
GlobeNewswire - Thu Aug 04, 6:50AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane and gemcitabine in patients with advanced metastatic pancreatic cancer.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.24 (-0.06), SCYX: 2.89 (+0.07), CFRX: 2.27 (unch), MNTA: 12.02 (+0.02), KERX: 4.10 (-0.15)

Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of M281, an anti-FcRn monoclonal antibody, for the treatment of autoimmune diseases.
MNTA: 12.02 (+0.02)

Shares of MNTA Up 26.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:03AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.91% as of today's recent price of $12.12.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 187.18 (-3.04), MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
GlobeNewswire - Sat Jun 04, 8:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane) and gemcitabine (gem) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2016 ASCO Annual Meeting, from 8:00 to 11:30 am CDT (Abstract #4117 / Poster #109) in Chicago, IL.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Shares Up 26.4% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Wed Jun 01, 1:35PM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.39% as of today's recent price of $12.07.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed May 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37 Annual Healthcare Conference will be webcast on Wednesday, June 8 at 8 a.m. PT.
MNTA: 12.02 (+0.02)

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.25 (unch), OGXI: 0.54 (-0.03), AMGN: 170.06 (-0.70), LLY: 77.75 (-0.02), BMY: 57.39 (+0.15), MNTA: 12.02 (+0.02), CELG: 106.74 (-0.28), EXEL: 11.15 (+0.11)

Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
MNTA: 12.02 (+0.02)

Momenta (MNTA) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:20PM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 35 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 40 cents.
SHPG: 187.18 (-3.04), MYL: 42.36 (-0.39), BXLT: 46.02 (-0.18), MNTA: 12.02 (+0.02)

Momenta reports 1Q loss
Automated Insights - Tue May 03, 7:26AM CDT
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Tuesday reported a loss of $24 million in its first quarter.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2016.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its first quarter 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 9:00 a.m. EDT on Tuesday, May 3, 2016.
MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
DB: 14.75 (+0.36), MNTA: 12.02 (+0.02)

Momenta Pharmaceuticals Announces Date of First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016.
MNTA: 12.02 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 36

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 102

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 111

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 42

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 319

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Smart Waste Management Market Growth Insights

Updated Category News Views 124

Overview of the Smart Waste Management Market In recent years, the smart waste management market has garnered substantial attention, projected to transition from $2.2 billion in valuation to an impressive $8.3 billion. This surge reflects a remarkable compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. The driving force behind this growth stems from increasing...

Continue Reading
Exploring the Collaborative Spirit at the China-US Event

Updated Category News Views 150

Celebrating Cultural Connections The recent 'My China Album' event highlighted the importance of cultural exchanges between the United States and China, focusing on the shared journeys and experiences of citizens from both nations. Strengthening Relations through Understanding During this special occasion, the ambassador emphasized the collaborative spirit that can propel...

Continue Reading
Exciting New Active Adult Community Launches in Central Oregon

Updated Category News Views 143

Welcoming Active Adults to Dry Canyon Introducing Dry Canyon, an extraordinary gated community designed specifically for those aged 55 and better. This remarkable development offers active adults a perfect blend of resort-style living and scenic beauty, all nestled in the heart of Central Oregon. As part of this celebration, Lennar, a well-respected name among...

Continue Reading
XTI Aerospace Announces Upcoming Town Hall for Stakeholders

Updated Category News Views 153

XTI Aerospace Invites Stakeholders to Upcoming Town Hall Updates on Tri-Fan 600, Valkyrie AI and Vanguard Platform ENGLEWOOD, Colo. – XTI Aerospace, Inc. (NASDAQ: XTIA) is at the forefront of advancing vertical flight technologies. The company is making exciting progress with its next-generation vertical takeoff and landing (VTOL) aircraft, the TriFan 600. XTI Aerospace...

Continue Reading
Big Lots Launches Discounts and Donations for Vets in November

Updated Category News Views 47

Big Lots Supports Veterans and Active Military with November Campaigns Every November, Big Lots makes a concerted effort to give back to veterans and active military members. This initiative is a part of their commitment to recognizing the sacrifices made by those who serve our country. Highlighting their respect for military service, Big Lots introduces various discounts...

Continue Reading